• 1. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 2. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 3. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 4. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 5. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119

Recent Advances in the Study of 2-Phenylimidazo[1,2-a]pyrimidine-3-carboxylic Acid (CAS: 123533-43-7)

The compound 2-phenylimidazo[1,2-a]pyrimidine-3-carboxylic acid (CAS: 123533-43-7) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential therapeutic applications. This heterocyclic scaffold is known for its diverse pharmacological properties, including anti-inflammatory, antimicrobial, and anticancer activities. Recent studies have focused on elucidating its mechanism of action, optimizing its synthetic pathways, and exploring its structure-activity relationships (SAR) to enhance its efficacy and selectivity.

A 2023 study published in the Journal of Medicinal Chemistry investigated the role of 2-phenylimidazo[1,2-a]pyrimidine-3-carboxylic acid as a potent inhibitor of protein kinases involved in cancer cell proliferation. The researchers employed molecular docking and kinetic assays to demonstrate its high affinity for the ATP-binding sites of specific kinases, such as EGFR and BRAF. The study also highlighted the compound's ability to induce apoptosis in vitro, suggesting its potential as a lead compound for targeted cancer therapies.

In addition to its anticancer properties, recent research has explored the antimicrobial potential of this compound. A 2022 paper in Bioorganic & Medicinal Chemistry Letters reported its efficacy against drug-resistant bacterial strains, including MRSA and Pseudomonas aeruginosa. The study attributed this activity to the compound's ability to disrupt bacterial cell membrane integrity and inhibit essential enzymes involved in bacterial metabolism. These findings underscore its potential as a novel antibiotic scaffold in an era of increasing antimicrobial resistance.

From a synthetic chemistry perspective, advancements have been made in the efficient production of 2-phenylimidazo[1,2-a]pyrimidine-3-carboxylic acid. A 2023 Organic Process Research & Development article detailed a scalable, one-pot synthesis method using microwave-assisted reactions, which significantly improved yield and reduced reaction times compared to traditional methods. This innovation is critical for facilitating further pharmacological studies and potential industrial-scale production.

Ongoing clinical and preclinical studies are investigating the pharmacokinetic profile and toxicity of derivatives of this compound. Preliminary results suggest favorable oral bioavailability and manageable toxicity profiles, making it a promising candidate for further drug development. However, challenges remain in optimizing its metabolic stability and tissue distribution, which are the focus of current structure-activity relationship studies.

In conclusion, 2-phenylimidazo[1,2-a]pyrimidine-3-carboxylic acid (CAS: 123533-43-7) represents a versatile scaffold with significant potential in multiple therapeutic areas. Recent research has expanded our understanding of its biological targets, synthetic accessibility, and pharmacological properties. Future studies are expected to focus on clinical translation and the development of more potent and selective analogs for specific disease indications.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)